If you answered "Yes" to any of the above, this product is right for you
Cagrilintide also has one of the lowest GI odds ratios among the incretin and amylin compound class in a 2025 Bayesian network meta-analysis of multi-target obesity therapies the relevance for the stack is that adding cagrilintide to retatrutide may not compound GI burden as severely as adding a second GLP-1 agonist would
Tirzepatide produces average weight loss of 16% to 22.5% of body weight over 72 weeks in clinical trials
Individuals struggling with obesity, insulin resistance, diabetes, unwelcome signs of aging, and hormone imbalances, including thyroid disorders and polycystic ovary syndrome (PCOS), can rely on Transcend Total Body Rejuvenation
Rather than simply masking signs of aging, the peptide appears to support some of the biological systems that influence skin health beneath the surface
& Castenholz, R